Fluoxetine as a Potential DPP-4 Inhibitor: An In Silico Validated Molecular Docking Study with Implications for Type 2 Diabetes

In the human body, a delicate balance keeps blood sugar levels steady, a process managed by a group of hormones that tell the pancreas to release insulin. One of the key regulators in this system is an enzyme called dipeptidyl peptidase-4, or DPP-4 for short. Think of this enzyme as a pair of molecular scissors that snips these helpful hormones, turning them off and allowing blood sugar to rise. When this happens too quickly, it contributes to type 2 diabetes, a condition where the body struggles to control glucose. To treat this, doctors often use drugs designed to block those scissors, keeping the hormones active longer and helping to lower blood sugar. At the same time, millions of people live with depression, a condition often treated with a class of medications known as selective serotonin reuptake inhibitors, or SSRIs. One of the most common SSRIs is fluoxetine, a drug that has been used for decades to lift mood.

For years, doctors have noticed something curious: some patients taking fluoxetine for depression also seem to experience changes in their blood sugar, sometimes showing improvements in how their bodies handle glucose. This observation has led to a question that bridges two very different fields of medicine: could a drug designed for the brain also be interacting with the enzyme that controls blood sugar? If fluoxetine were to block DPP-4, it might offer a rare double benefit, treating both depression and diabetes with a single pill. However, proving this requires more than just noticing a pattern; it requires seeing exactly how the drug fits into the molecular machinery of the body.

A researcher named Arya Regmi set out to investigate this possibility using a powerful form of digital exploration called molecular docking. Instead of mixing chemicals in a test tube, the study took place inside a computer, where the researcher built a virtual model of the DPP-4 enzyme and a virtual model of the fluoxetine molecule. The goal was to see if fluoxetine could physically fit into the active site of the enzyme, the specific pocket where the "scissors" usually work. To ensure the computer model was accurate, the researcher first tested the system by removing the natural molecule that usually sits in that pocket and trying to put it back in. The computer successfully placed it back in the correct spot with a high degree of precision, confirming that the digital tools were reliable enough to test new ideas.

With the system validated, the researcher introduced the virtual fluoxetine molecule to the enzyme. The computer ran thousands of simulations, twisting and turning the drug molecule to find the most comfortable position within the enzyme's binding site. The results showed that fluoxetine did indeed fit. It settled into the pocket in a way that allowed it to form specific connections with the enzyme's internal structure, including bonds with key amino acids that are known to be important for the enzyme's function. The computer calculated a binding strength of -7.7 kilocalories per mole, a value that suggests the drug could hold onto the enzyme with reasonable stability. To be sure this wasn't just a fluke of one specific computer program, the researcher ran the same test again using a different software method, which produced a very similar result, reinforcing the idea that the drug and the enzyme have a genuine affinity for one another.

The study also looked at how fluoxetine compared to existing diabetes drugs. The computer simulations suggested that fluoxetine received a more favorable docking score than Saxagliptin but a less favorable score than Linagliptin. However, the researcher was careful to note that these docking scores are empirical approximations and should not be interpreted as experimental binding free energies or as a direct measure of comparative inhibitory potency. A strong fit in a computer simulation does not automatically mean the drug will work as a medicine in a human body. The study also checked if fluoxetine might accidentally bind to a related enzyme called DPP-9, which could cause unwanted side effects. The results showed that fluoxetine may bind more readily with DPP-9 than with DPP-4, but the researcher emphasized that this binding does not necessarily mean potential inhibition, and the lack of spatial overlap with the native ligand does not by itself establish a lack of inhibitory activity.

Beyond the binding mechanics, the study examined the drug's journey through the body using digital predictions. The models suggested that if a person took fluoxetine, their intestines would absorb it very efficiently, and it would travel well through the bloodstream to reach various tissues. The drug was also predicted to be stable enough to avoid immediate breakdown by the liver, though it might interact with some of the body's natural chemical processing systems. These findings painted a picture of a drug that could theoretically reach the right place in the body in sufficient quantities to do its work.

Despite these promising digital results, the researcher emphasized that this study is only the beginning of the story. The work was entirely a simulation, a sophisticated guess based on the laws of physics and chemistry as they apply to molecules in a computer. It showed that fluoxetine can fit into the DPP-4 enzyme and that it might block it, but it did not prove that it actually does so in a living person. The study explicitly stated that no experiments were performed in a lab or on patients to confirm these findings. The computer cannot measure the actual concentration of the drug in a human bloodstream or prove that it lowers blood sugar in a real body.

The conclusion of the paper is one of cautious optimism. The digital evidence supports the idea that fluoxetine is a candidate worthy of further investigation. It suggests that the drug has the physical shape and chemical properties to interact with the enzyme that controls blood sugar, offering a plausible explanation for the metabolic changes some patients have experienced. However, the researcher made it clear that this is not a discovery of a new cure, but rather a hypothesis generated by a computer. To move from a digital possibility to a medical reality, scientists would need to take the next step: testing the drug directly against the enzyme in a laboratory setting to measure its actual power and safety. Until those real-world tests are done, fluoxetine remains a potential key to a dual-purpose treatment, waiting for the final lock to be turned by experimental proof.